Skip to content

Study · Not a test of the peptide alone · 2020

2 results

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.

Braidy N, Liu Y

Experimental gerontology7 Jan 2020Cited by 67 (Europe PMC)

PMID31917996 (opens in a new tab)DOI10.1016/j.exger.2020.110831 (opens in a new tab)PepBankPUB-31917996
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  1. 01AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneOther designEfficacy outcome

    Across reviewed studies, pooled NAD+ precursors, NAD+ and NADH generally had favorable outcomes on several age-related disorders.

    In plain wordsAcross reviewed preclinical and clinical studies, pooled NAD+ precursors, NAD+ and NADH generally had favorable outcomes on several age-related disorders.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    MixedAge-related disorders
    Study

    n: not reported in source

    Outcome group
    Aging markers · Aging and longevity

    Source sentences

    Summary
    Most studies indicated that the NAD+ precursors NAM, NR, nicotinamide mononucleotide (NMN), and to a lesser extent NAD+ and NADH had a favourable outcome on several age-related disorders associated with the accumulation of chronic oxidative stress, inflammation and impaired mitochondrial function.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  2. 02AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneOther designSafety outcome

    Across reviewed studies, pooled NAD+ compounds had a limited acute toxicity profile, with limited evidence.

    In plain wordsAcross reviewed preclinical and clinical studies, pooled NAD+ compounds had limited acute toxicity, but evidence was limited.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    Direction not reportedAcute toxicity profile
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    While these compounds presented with a limited acute toxicity profile, evidence is still quite limited and long-term human clinical trials are still nascent in the current literature.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.